Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
PR Newswire•27/10/2026•06:50 ET
0
Key Highlights
- ➤Any vomiting 43.0% vs 58.5% placebo; 27% relative reduction, p=0.006
- ➤Frequent multi-day vomiting 6.3% vs 15.9%; 60% relative reduction, p=0.008
- ➤Extreme vomiting 2.8% vs 14.6%; 81% relative reduction, p=0.0003
- ➤Vanda plans FDA discussions and an sNDA for GLP-1-induced vomiting prevention
- ➤NEREUS generally well tolerated; no new safety signals observed
Expert Statements
Mihael H. Polymeropoulos, President, CEO and Chairman of the Board of Vanda Pharmaceuticals
“These results demonstrate that NEREUS can meaningfully reduce vomiting and frequent multi-day vomiting induced by GLP-1 therapy, which are key contributors to treatment discontinuation,”
Mihael H. Polymeropoulos, President, CEO and Chairman of the Board of Vanda Pharmaceuticals
“The consistency and magnitude of the effects observed across this program could offer significant benefit to the millions of people seeking or using GLP1 therapies.”
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting PR Newswire
NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting
Get started
Create a free account to read the full story.